Immunotherapy for colorectal cancer: where are we heading?
D Basile, SK Garattini, M Bonotto… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: In the last few years, significant advances in molecular biology have provided
new therapeutic options for colorectal cancer (CRC). The development of new drugs that …
new therapeutic options for colorectal cancer (CRC). The development of new drugs that …
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients
D Basile, A Parnofiello, MG Vitale… - Journal of cachexia …, 2019 - Wiley Online Library
Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and
loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced …
loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced …
[HTML][HTML] Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous …
S Lonardi, AA Prete, F Morano, M Messina… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
[HTML][HTML] Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
F Loupakis, R Moretto, G Aprile, M Muntoni… - British journal of …, 2016 - nature.com
Background: In metastatic colorectal cancer (mCRC), BRAFV600E mutation has been
variously associated to specific clinico-pathological features. Methods: Two large …
variously associated to specific clinico-pathological features. Methods: Two large …
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
Background. No prospective trials have specifically addressed the efficacy and safety of
panitumumab in elderly patients with metastatic colorectal cancer (CRC). We aimed at …
panitumumab in elderly patients with metastatic colorectal cancer (CRC). We aimed at …
[HTML][HTML] Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations
C Neuzillet, AC Gardini, B Brieau, C Vivaldi… - European Journal of …, 2019 - Elsevier
Background The benefit of second-line chemotherapy (L2) over standard first-line (L1)
gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in advanced …
gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in advanced …
[HTML][HTML] Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 …
C Antoniotti, WM Korn, F Marmorino, D Rossini… - European Journal of …, 2021 - Elsevier
Background We performed a comprehensive genomic profiling of tumour samples from
metastatic colorectal cancer (mCRC) patients enrolled in the TRIBE2 study to assess the …
metastatic colorectal cancer (mCRC) patients enrolled in the TRIBE2 study to assess the …
[HTML][HTML] Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with …
C Cremolini, F Marmorino, F Bergamo, G Aprile… - European Journal of …, 2019 - Elsevier
Background Alternating induction and maintenance phases is a common strategy in
metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a …
metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a …
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
F Pietrantonio, G Aprile, L Rimassa, P Franco… - Radiotherapy and …, 2015 - Elsevier
Background The prognosis of brain metastases (BM) in colorectal cancer (CRC) is extremely
poor, but the incidence is increasing. The performance of existing prognostic classifications …
poor, but the incidence is increasing. The performance of existing prognostic classifications …
[HTML][HTML] Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials
G Aprile, C Fontanella, M Bonotto, K Rihawi… - Oncotarget, 2015 - ncbi.nlm.nih.gov
The identification of new surrogate endpoints for advanced colorectal cancer is becoming
crucial and, along with drug development, it represents a research field increasingly studied …
crucial and, along with drug development, it represents a research field increasingly studied …